EUVIMEDEUVIMED entdecken
Open Access

Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia

Hagop Kantarjian iD, Wei-Ying Jen iD, Eitan Kugler iD, Rebecca Garris, Sherry Pierce, Nitin Jain, Nicholas J Short iD, Issa Khouri iD, Sanam Loghavi, Fadi G Haddad iD, Farhad Ravandi, Elias Jabbour iD

Cancer · 01.08.2026 · 132 (15)

DOI: 10.1002/cncr.70533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 21.07.2026. Verfasst von Hagop Kantarjian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The approval of the BCR::ABL tyrosine kinase inhibitors (TKIs) and blinatumomab have improved outcomes in Ph‐positive B‐acute lymphoblastic leukemia (ALL). However, patients still relapse, and their outcomes in the TKI era have yet to be defined.

Methods

Patients with relapsed/primary refractory Philadelphia chromosome (pH)‐positive B‐ALL ≥16 years old treated in first salvage from 1992 to 2025 were analyzed.

Results

A total of 165 patients (median age, 48; range, 17–78 years) were analyzed. The overall complete remission (CR) rate was 80%. By multivariate analysis, only the use of TKIs was associated with a significant benefit for achieving CR. The median overall survival (OS) was 15 months. The 3‐year OS rate was 31%. The 3‐year OS rate was 57% with third‐generation TKI combinations, 38% with second‐generation TKI combinations, 8% with imatinib combinations, and 0% without TKIs. By multivariate analysis, three variables were independently predictive of survival: TKI‐based therapy (hazard ratio [HR], 0.10–0.49; p values all

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansAdultMiddle AgedFemaleAdolescentMaleAgedYoung AdultPhiladelphia ChromosomeSalvage TherapyImatinib MesylateRemission InductionAntibodies, BispecificTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

ALL salvage therapyCARTblinatumomabinotuzumab

Substanzen

Protein Kinase InhibitorsblinatumomabImatinib MesylateAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Hagop Kantarjian, Wei-Ying Jen, Eitan Kugler, Nicholas J Short, Issa Khouri, Fadi G Haddad, Elias Jabbour

Förderung

  • NCI NIH HHS

Zitieren

APA

Kantarjian, H., Jen, W. Y., Kugler, E., Garris, R., Pierce, S., Jain, N., Short, N. J., Khouri, I., Loghavi, S., Haddad, F. G., Ravandi, F., & Jabbour, E. (2026). Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer, 132(15). https://doi.org/10.1002/cncr.70533

Vancouver

Kantarjian H, Jen WY, Kugler E, Garris R, Pierce S, Jain N, et al. Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer. 2026;132(15). doi:10.1002/cncr.70533

BibTeX
@article{Kantarjian2026,
  author = {Kantarjian, Hagop and Jen, Wei-Ying and Kugler, Eitan and Garris, Rebecca and Pierce, Sherry and Jain, Nitin and Short, Nicholas J and Khouri, Issa and Loghavi, Sanam and Haddad, Fadi G and Ravandi, Farhad and Jabbour, Elias},
  title = {Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {15},
  doi = {10.1002/cncr.70533}
}
Kostenlos starten →